Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 507

1.

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W.

J Clin Oncol. 2006 Jun 20;24(18):2707-14.

PMID:
16782910
2.

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.

J Clin Oncol. 2006 Jun 20;24(18):2715-22.

PMID:
16782911
3.

Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.

Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K.

Brain Pathol. 2008 Jul;18(3):360-9. doi: 10.1111/j.1750-3639.2008.00129.x. Epub 2008 Mar 26.

PMID:
18371182
4.

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.

Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ.

Cancer. 2005 Feb 15;103(4):802-9.

5.
6.

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M.

J Clin Oncol. 2013 Jan 20;31(3):337-43. doi: 10.1200/JCO.2012.43.2674. Epub 2012 Oct 15.

7.

Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.

Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW.

Clin Cancer Res. 2003 Mar;9(3):981-90.

8.

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.

Quon H, Abdulkarim B.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007104. doi: 10.1002/14651858.CD007104. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD007104.

PMID:
18425979
9.

Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.

Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH.

Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):58-66.

PMID:
12007942
10.

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52.

PMID:
15001257
11.

A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404.

Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr.

Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1109-15.

PMID:
10613302
12.

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG.

Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):825-30.

PMID:
11020580
13.

A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.

Streffer J, Schabet M, Bamberg M, Grote EH, Meyermann R, Voigt K, Dichgans J, Weller M.

J Neurol. 2000 Apr;247(4):297-302.

PMID:
10836623
14.

Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K.

J Clin Oncol. 2013 Jan 20;31(3):344-50. doi: 10.1200/JCO.2012.43.2229. Epub 2012 Oct 15.

PMID:
23071237
15.

Combined treatment modality for anaplastic oligodendroglioma: a phase II study.

Jeremic B, Shibamoto Y, Gruijicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A, Aleksandrovic J.

J Neurooncol. 1999 Jun;43(2):179-85.

PMID:
10533731
16.

Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial.

Taphoorn MJ, van den Bent MJ, Mauer ME, Coens C, Delattre JY, Brandes AA, Sillevis Smitt PA, Bernsen HJ, Frénay M, Tijssen CC, Lacombe D, Allgeier A, Bottomley A; European Organisation for Research and Treatment of Cancer.

J Clin Oncol. 2007 Dec 20;25(36):5723-30.

PMID:
18089866
17.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

18.

A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.

Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE.

J Neurooncol. 2008 Sep;89(2):187-93. doi: 10.1007/s11060-008-9603-8. Epub 2008 May 6.

PMID:
18458821
19.

Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.

Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, Pace A, Giangaspero F, Osti MF, Enrici RM.

J Neurooncol. 2014 Jan;116(2):275-82. doi: 10.1007/s11060-013-1288-y. Epub 2013 Oct 26.

PMID:
24162810
20.

Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.

Iwadate Y, Matsutani T, Hasegawa Y, Shinozaki N, Higuchi Y, Saeki N.

J Neurooncol. 2011 May;102(3):443-9. doi: 10.1007/s11060-010-0340-4. Epub 2010 Aug 19.

PMID:
20721680

Supplemental Content

Support Center